Compare Amgen, Inc. (AMGN) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Freshworks Inc — how do they compare? Amgen, Inc. trades at $416.97 (market cap $224.14B), while Freshworks Inc trades at $11.6 (market cap $3.31B). The key difference: Amgen, Inc. is far larger — about 67.7× Freshworks Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| AMGN | FRSH | |
|---|---|---|
Market Cap | $224.14B | $3.31B |
Sector | Health | Technology |
52-Week High | $417.20 | $13.97 |
52-Week Low | $271.18 | $6.88 |
Enterprise Value | $267.45B | $2.68B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
Freshworks (FRSH) trades at $11.66, down 2.67% on the day, as the stock consolidates near key technical levels. The company demonstrates strong fundamental improvement with 16% revenue growth in Q2 2026 and achieving GAAP profitability for the first time this year. Recent positive developments include FedRAMP certification progress and Gartner leadership recognition, while analyst sentiment remains evenly split between Buy and Hold ratings with a $16.50 consensus price target representing significant upside potential.
The outlook appears favorable given Freshworks' transition to profitability, expanding AI capabilities, and strong EX business growth. Key risks include competitive pressures in the SaaS sector and the need to maintain recent momentum. With attractive valuation metrics and positive cash flow trends, the stock presents a compelling opportunity for investors seeking exposure to the growing service operations software market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
